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Adult-Onset Vitelliform Macular 
Dystrophy caused by BEST1 
p.Ile38Ser Mutation is a Mild 
Form of Best Vitelliform Macular 
Dystrophy
Ikhyun Jun1,2,3, Joon Suk Lee3, Ji Hwan Lee1, Christopher Seungkyu Lee1, Seung-il Choi2, Heon 
Yung Gee  3, Min Goo Lee3 & Eung Kweon Kim1,2,4
Adult-onset vitelliform macular dystrophy (AVMD) is a common and benign macular degeneration 
which can be caused by BEST1 mutation. Here, we investigated the clinical characteristics associated 
with a newly identified BEST1 mutation, p.Ile38Ser and confirmed the associated physiological 
functional defects. The 51-year-old patient presented bilateral small subretinal yellow deposits. 
Consistent with AVMD, the corresponding lesions showed hyperautofluorescence, late staining in 
fluorescein angiography, and subretinal hyper-reflective materials in spectral-domain optical coherence 
tomography. Genetic analysis demonstrated that the patient presented with a heterozygous p.Ile38Ser 
BEST1 mutation. Surface biotinylation and patch clamp experiments were performed in transfected 
HEK293T cells. Although, the identified BEST1 mutant maintains normal membrane expression, 
p.Ile38Ser mutant showed significantly smaller currents than wild type (WT). However, it showed larger 
currents than other BEST1 mutants, p.Trp93Cys, causing autosomal dominant best vitelliform macular 
dystrophy (BVMD), and p.Ala195Val, causing autosomal recessive bestrophinopathy (ARB). The cells 
expressing both WT and each BEST1 mutant showed that the functional defect of p.Ile38ser was milder 
than that of p.Trp93Cys, whereas combination of p.Ala195Val with WT showed good current. We 
identified and described the phenotype and in vitro functions of a novel BEST1 mutation causing AVMD. 
AVMD induced by p.Ile38Ser BEST1 mutation is a mild form of BVMD.
Bestrophin-1 (BEST1, also known as VMD2) was first identified in Best vitelliform macular dystrophy (BVMD, 
Best disease), a disease associated with BEST1 mutations1–3. BEST1 is predominantly expressed in the basolateral 
membrane of the retinal pigment epithelium (RPE)4. X-ray structure of chicken BEST1, sharing 74% of sequence 
homology with human BEST1, indicated that BEST1 forms a homo-pentamer and functions as a Ca2+-activated 
chloride (Cl−) channel (CaCC)5. Moreover, BEST1 appears to function as a regulator of intracellular calcium sig-
naling6. More than 200 mutations of this gene have been reported to generate various ocular diseases, which are 
collectively referred to as bestrophinopathy. Bestrophinopathy includes at least five clinically distinct categories, 
BVMD, adult-onset vitelliform macular dystrophy (AVMD), autosomal recessive bestrophinopathy (ARB), auto-
somal dominant vitreoretinochoroidopathy (ADVIRC), and retinitis pigmentosa (RP)2, 3.
AVMD is one of the most common forms of macular degeneration7. The age of AVMD onset is highly vari-
able, but patients have a tendency to remain asymptomatic until the fifth decade3, 7. The clinical characteristics 
of AVMD are relatively benign, including a small subretinal vitelliform macular lesion, a slower progression 
of disease, and a slight deterioration in electrooculography (EOG)3, 7. In some cases, AVMD is associated with 
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autosomal dominant inheritance8, 9, with mutations in PRPH210, BEST111, IMPG112, or IMPG213. Fluctuating 
expression and decreased penetrance could partly explain the scarcity of a clear inheritance pattern.
Allikmets and colleagues published the first report describing the BEST1 mutation, p.Ala146Lys, in a patient 
with AVMD in 199914. The authors screened for BEST1 mutation in patients with age-related macular degener-
ation (AMD) and other maculopathies and concluded that BEST1 mutations could cause various disease phe-
notypes. Subsequently, four additional BEST1 mutations, including p.Thr6Pro, p.Arg47His, p.Ala243Val, and 
p.Asp312Asn, were identified in patients with AVMD11. Since then, no further mutations in BEST1 have been 
identified by genetic screening of patients with AVMD15–19, although late onset best macular dystrophy with 
BEST1 mutations has been investigated20.
Currently, because of similar clinical characteristics, AVMD induced by BEST1 mutations is considered a 
late-onset and mild form of BVMD2, 3, 7, although there is no case report or no combined experimental evidence. 
No study has investigated the direct association between BEST1 mutation and AVMD pathophysiology. In this 
study, we present an AVMD case presenting with a novel BEST1 mutation, p.Ile38Ser, and propose that BEST1 
mutation is the causative factor of AVMD based on molecular and electrophysiological in vitro experiments.
Results
Clinical findings. The demographic and clinical details of the patient with AVMD are summarized in 
Table 1. A 51-year-old man was referred to our hospital because of retinal lesions in both eyes detected during 
health checkup. His best-corrected visual acuity was 20/20 in the right eye and 20/22 in the left eye. The patient 
was slightly myopic and his intraocular pressure was within the normal range. No specific sign was detected in 
his anterior segment of the eyes. The fundus showed small subfoveal yellowish deposits and some drusens on 
the right eye, and one-fourth of the disc area sized subfoveal yellowish deposits on the left eye (Fig. 1a and b). 
Increased autofluorescence at the yellowish subfoveal deposits was detected by blue-light autofluorescence imag-
ing (Fig. 1c and d). The fluorescein angiography showed staining of the vitelliform material corresponding to the 
area of retinal lesion (Fig. 1e and f). SD-OCT showed well demarcated and dome-shaped subretinal hyper-re-
flective material in the affected lesion (Fig. 1g and h). Full-field ERG showed the normal range of scotopic and 
photopic responses. The EOG showed a decreased light rise (Arden ratio, 1.6 (OD), 1.4 (OS)). His clinical mani-
festations did not change during the 2-year follow-up.
Genetic findings. A heterozygous c.T113G missense mutation (p.Ile38Ser) was detected in the BEST1 gene of 
the patient, suggesting the autosomal dominant inheritance of this mutation (Fig. 2a). We also examined PRPH2, 
IMPG1, and IMPG2, which are other known genes for AVMD, by Sanger sequencing. Several nonsynonymous 
variants were detected (Supplementary Table S1), but all of them are reported as single nucleotide polymorphism 
(SNP), of which minor allele frequencies are greater than 1%; therefore, they are not likely to be disease-causing. 
The BEST1 p.Ile38Ser mutation has not been previously reported in patients with BEST1-associated disease, or in 
SNP databases such as dbSNP or Exome Aggregation Consortium (ExAC) (Table 1). This mutation is not found 
in the National Biobank of Korea (NBK) data of whole genome sequencing of 397 healthy individuals or in our 
in-house whole exome sequencing data (59 subjects) described in our previous study21. The amino acid residue 
affected by this missense mutation is located in the transmembrane (TM) domain 1, which is well conserved 
throughout evolution down to Danio rerio (Table 1 and Fig. 2b and c). Moreover, several prediction algorithms 
suggested that p.Ile38Ser mutation has high disease-causing probability (Table 1).
In vitro study. We conducted in vitro experiments to examine functional defects caused by this mutation. 
We evaluated the membrane expression of BEST1 p.Ile38Ser mutant. We performed surface biotinylation assays, 
which can detect proteins only on the plasma membrane, after transfection of wild type (WT) and mutant 
hBEST1 clones into HEK293T cells (Figs. 3a and b). BEST1 p.Ile38Ser mutant is expressed in the membrane 
as WT and other mutants, p.Trp93Cys and p.Ala195Val, which were previously shown to be expressed in the 
Sex
Age 
(yr)
Decimal Visual 
Acuity (Spherical 
Equivalent, D) ERG
EOG, 
Arden 
Ratio Nucleotide 
changea
Amino 
acid 
change
Amino acid 
sequence 
conservationb
Frequencies 
in the 
dbSNP 
databasec
Frequencies 
in the ExAC 
databased
Frequencies 
in the NBK 
databasee PP2f MTg
PRO-
VEANh SIFTiOD OS OD OS OD OS
M 51 1.0 (−0.375)
0.9 
(−0.25) WNL WNL 1.6 1.4 c.113T > G
p.
Ile38Ser D. rerio ND ND ND
PD 
(0.999)
DC 
(1.000)
Del 
(−3.27)
Dam 
(0.033)
Table 1. Demography, Clinical Findings, and In Silico Analysis of the BEST1 mutation. Abbreviations are as 
follows: D, diopter; Dam, damaging; DC, disease causing; Del, deleterious; EOG, electro-oculogram; ERG, 
electroretinogram; M, male; ND, no data or DNA available; OD, right eye; OS, left eye; PD, probably damaging; 
PP2, PolyPhen-2 prediction score Humvar; PROVEAN, Protein Variation Effect Analyzer; SIFT, Sorting 
Intolerant from Tolerant; SNP, single nucleotide polymorphism; WNL, within normal limits; yr, years. acDNA 
mutations are numbered according to human cDNA reference sequence NM_004183; +1 corresponds to the 
A of ATG translation initiation codon. bAmino acid residue is continually conserved throughout evolution 
including the species as indicated. cdbSNP database (http://www.ncbi.nlm.nih.gov/SNP). dExAC browser 
(http://exac.broadinstitute.org/). eNational Biobank of Korea, the Centers for Disease Control and Prevention. 
fPolyPhen-2 prediction score HumVar ranges from 0 to 1.0; 0 = benign, 1.0 = probably damaging (http://
genetics.bwh.harvard.edu/pph2/). gMutation taster (http://www.mutationtaster.org/). hPROVEAN (http://
provean.jcvi.org/index.php). iSIFT (http://sift.jcvi.org/).
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membrane (Fold change; WT = 1; p.Ile38Ser = 0.85 ± 0.12; p.Ala195Val = 0.96 ± 0.07; p.Trp93Cys = 1.09 ± 0.13; 
WT + p.Ile38Ser = 1.14 ± 0.15; WT + p.Ala195Val = 1.05 ± 0.14; WT + p.Trp93Cys = 1.17 ± 0.21; P = 0.589)22. 
Membrane expression of WT and p.Ile38Ser was also confirmed by immunocytochemistry (Supplementary 
Fig. S1). WT and mutant BEST1 exhibited no difference in the detergent solubility assay, which evaluates intra-
cellular aggregation (Figs. 3c and d, Fold change; WT = 1, p.Ile38Ser = 1.13 ± 0.08; p.Trp93Cys = 1.17 ± 0.09; 
p.Ala195Val = 1.10 ± 0.09; P = 0.300).
Subsequently, we measured whole-cell currents of the WT BEST1 and mutants after activation by calcium in 
transfected HEK293T cells (Fig. 4, Supplementary Table S2). WT BEST1 generated significantly larger currents 
Figure 1. Clinical features of the patient. (a,b) Color fundus photographs showing bilateral, round subretinal 
yellowish deposits (vitelliform) in the posterior pole. (c,d) Blue light autofluorescence imaging showed intense 
hyper-autofluorescence at the corresponding yellowish deposit lesions. (e,f) Corresponding lesions showed 
diffuse hyperfluorescence in the late-phase images of fluorescein angiography. (g,h) Horizontal spectral-domain 
optical coherence tomography images through fovea showed well demarcated subretinal hyper-reflective 
material in the affected lesion.
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than those observed in the mock-transfected HEK293T cells as reported in previous studies (P < 0.001)22, 23. In 
addition, the currents in the cells expressing p.Ala195Val and p.Trp93Cys were significantly smaller than those 
in cells expressing WT, consistent with previous studies (Supplementary Table S2)22. p.Ile38Ser mutant showed a 
smaller current, about 20% of WT BEST1, which was statistically significant (P < 0.001). However, the current of 
p.Ile38Ser was approximately 7 times larger than that of the p.Trp93Cys mutant, although it did not reach statis-
tical significance (Supplementary Table S2). These data suggest that the p.Ile38Ser mutation may result in a mild 
form of bestrophinopathy.
Figure 2. Genetic analysis of the patient identified a novel BEST1 mutation, p.Ile38Ser. (a) Sequencing traces 
of the mutation and wild type control. Altered nucleotide and amino-acid changes are indicated above the 
sequence traces. (b) Domain structure of BEST1. The transmembrane (TM) domains are depicted by orange 
colored bars. The BEST1 mutation is located in the TM1 domain. (c) Partial protein alignment of BEST1 TM1 
domain showed evolutionary conservation of the identified missense changes.
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Given that the patient was heterozygous for this mutation, we evaluated BEST1 function in HEK293T cells 
after co-expression of WT and p.Ile38Ser BEST1 (Fig. 5, Supplementary Table S2). Cells co-expressing WT 
and p.Ile38Ser BEST1 showed approximately one-third of the currents observed in cells expressing WT BEST1 
(P < 0.001). HEK293T cells co-transfected with plasmids expressing WT BEST1 and p.Ala195Val, known as an 
autosomal recessive mutant22–24, generated 80% of the current observed in cells expressing WT BEST1 (Fig. 5, 
Supplementary Table S2). Meanwhile, co-expression of an autosomal dominant-type mutant, p.Trp93Cys, and 
WT BEST1 resulted in the activation of diminutive currents as previously reported (Fig. 5, Supplementary 
Table S2)22. These findings suggest that p.Ile38Ser mutation is probably associated with autosomal dominant 
bestrophinopathy, presenting a milder phenotype than the classical BVMD mutant, p.Trp93Cys. Additionally, a 
threshold current of disease occurrence associated with BEST1 mutation might be located between the values of 
p.Ala195Val and p.Ile38Ser.
Structure analysis. A 3-dimensional protein modeling was performed to examine structural defects caused by 
the p.Ile38Ser mutation (Fig. 6). The side chain of Ile38 in TM1 domain protrudes toward the lipid membrane 
(Fig. 6b) and is composed of hydrophobic carbon, whereas the side chain of p.Ile38Ser mutant has oxygen resi-
dues, which may generate a repulsive force with the lipid membrane (Fig. 6c). Therefore, the mutation can affect 
the protein structure and function.
Discussion
AVMD is typically known to present with central round yellow deposit (<1 disc diameter), hyper-autofluorescent 
lesion, late staining in fluorescein angiography, and subnormal to normal EOG7. Our patient also presented a 
bilateral small hyper-autofluorescent, vitelliform macular lesion, and subnormal EOG (Arden ratio 1.6 for right 
Figure 3. BEST1 p.Ile38Ser mutation does not interfere with membrane expression. HEK293T cells were 
transfected with plasmids expressing wild type and mutant hBEST1. (a) Surface biotinylation assays of 
hBEST1 were performed. (b) Quantitation of multiple experiments shows that the membrane expression was 
not different among groups by ANOVA (P = 0.589). Fold changes relative to WT are provided. (c) Detergent 
solubility assay of wild type and mutant hBEST1. (d) Quantification of multiple experiments shows that the 
detergent solubility was not different among the groups by ANOVA (P = 0.300). Fold changes relative to WT 
are provided. Western blots were cropped to show specific bands only. For uncropped blots see Supplementary 
Fig. S2.
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eye, and 1.4 for left eye), consistent with AVMD. Despite these fundoscopic pathologies, he presented no symp-
tom, and his visual acuity was good in both eyes. The patient was first examined at age 51, and the clinical pheno-
types did not change during the 2-year follow-up. Interestingly, the left eye showed a larger lesion than the right 
eye, consistent with the lower visual acuity and Arden ratio in EOG of the left eye.
The BEST1 p.Ile38Ser mutation identified in this study is located in the TM1 domain, which is well conserved 
in all vertebrates (Table 1 and Fig. 2). The well conserved regions of a gene imply their involvement in physi-
ological functions and mutations can render the gene defective. Prediction of pathogenicity for this mutation 
also demonstrated a high likelihood of deterioration (Table 1). The side-chain of isoleucine is hydrophobic and 
protrudes into the lipid bilayer5, but the substituted serine contains a hydrophilic hydroxyl group in the side chain 
(Fig. 6). If the hydroxyl group protrudes, the repulsive force between the hydrophilic side chain and hydrophobic 
tails of phospholipids can be generated, causing structural disturbance.
Because the clinical features of AVMD are similar to those of early stage BVMD and the age of BVMD onset 
is highly variable, many groups have suggested that AVMD is a mild form of BVMD and presents the same 
spectrum2, 3. However, physiological and experimental evidence is insufficient and unsatisfactory. We conducted 
in vitro experiments to directly investigate the association between the novel variant of BEST1 (p.Ile38Ser) and 
AVMD. The membrane expression of the BEST1 p.Ile38Ser mutant was comparable to that of WT (Fig. 3) and 
similar to the expression of other autosomal dominant BEST1 mutations22, 25–27. The defect associated with p.Il-
e38Ser mutation is not likely to be due to deterioration of membrane localization. In fact, the pathogenesis of 
autosomal dominant BEST1 mutation mostly results from the assembly of a heteropentameric structure together 
with defective mutant and normal BEST1, which results in impairment of CaCC function5, 28. Therefore, intact 
membrane expression of BEST1 mutant can be associated with the development of the disease. The detergent 
solubility assay showed no difference between WT and p.Ile38Ser, indicating that the pathogenesis of p.Ile38ser 
is not related with protein insolubility.
Next, we evaluated the current activation of the BEST1 mutants by whole cell patch-clamp recording. The 
p.Ile38Ser mutant generated reduced calcium-activated currents, which verifies that this mutation is the causa-
tive factor of the disease (Fig. 4). The current generated by the p.Ile38Ser was bigger than those of p.Trp93Cy and 
p.Ala195Val, possibly explaining the mild clinical features of the patient with p.Ile38Ser mutation. Furthermore, 
co-expression of WT and p.Ile38Ser produced a small, but consistent, degree of currents, approximately 30% 
of that produced by WT BEST1, whereas p.Trp93Cys, a variant of BVMD, and WT elicited almost no current 
(Fig. 5). These data are consistent with subnormal to normal values of EOG in our patient and patients with 
AVMD and absent light rise in patients with BVMD, because EOG reflects a Cl− conductance in the basolateral 
membrane of the RPE where BEST1 is localized4, 29–31. In addition, p.Ala195Val, an autosomal recessive variant, 
Figure 4. p.Ile38Ser BEST1 mutant shows smaller currents compared to wild type (WT) BEST1 and bigger 
currents compared to p.Ala195Val or p.Trp93Cys mutants. (a–e) Representative traces of HEK293T cells 
transfected with EGFP alone (a), WT (b), p.Ile38Ser (c), p.Ala195Val (d), or p.Trp93Cys (e) BEST1. Voltage was 
stepped from a holding potential of 0 mV to between −100 and +100 mV in 20 mV steps. Step duration was 
2000 ms. (f) Current-voltage relationship of mock, WT, and mutant BEST1. Data are presented as mean ± SEM.
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showed much bigger currents than p.Ile38Ser when co-transfected with WT BEST1 (Fig. 5). Thus, we speculate 
that p.Ile38Ser mutation presents autosomal dominant inheritance with dominant negative character.
Yu and colleagues investigated other BEST1 variants associated with AVMD, p.Ala146Lys, p.Ala243Val, 
and p.Asp312Asn25, 26. These variants are also expressed on the cell surface membrane. Cells transfected with 
these variants alone presented very small calcium-activated currents, and those of cells co-transfected with plas-
mids expressing WT BEST1 and each variant were moderately increased, similarly to the p.Ile38Ser mutant. 
Additionally, the EOG values of patients presenting these mutations were normal or slightly below baseline11. 
These previous data support the hypothesis that AVMD is a mild form of BVMD. Furthermore, some BEST1 
mutations causing BVMD are associated with variable clinical features regarding age at onset, lesion size, and 
EOG results20. Such variable phenotypes of bestrophinopathy result from variable expression patterns and 
reduced penetrance of BEST1. Therefore, BEST1 activity as a calcium-activated Cl- channel, can determine the 
seriousness of the disease. We suggest that the degree of functional defect resulting from a certain BEST1 muta-
tion may dictate the phenotype as BVMD or AVMD.
This study has some limitations. We only identified one BEST1 mutation causing AVMD. Moreover, the 
patient refused clinical evaluation and genetic analysis of his family members. Hence, we were unable to trace his 
pedigree. We only confirmed a modest functional defect of p.Ile38Ser mutant, although several BEST1 mutants 
causing AVMD are present. Nonetheless, this study is valuable, because it is the first study linking AVMD clinical 
features and molecular patho-mechanisms caused by a BEST1 mutation. Furthermore, our results suggest that 
increasing ion channel activity of BEST1 mutants could be a treatment option for bestrophinopathy, including 
BVMD. If we can improve the function of BEST1 mutant to one-third that of WT, BVMD, which causes visual 
loss, may be shifted to AVMD, which is benign. As for Ivacaftor, a CFTR potentiator, which has become a cor-
nerstone drug for the treatment of cystic fibrosis32, 33, the development of a BEST1 potentiator can be a paradigm 
shift for the treatment of bestrophinopathy and even provide a complete cure. To examine more physiological 
pathomechanisms of BEST1 mutant, the experiments in RPE cells are needed in the future studies.
Figure 5. p.Ile38Ser mutation induces mild deterioration of protein function. (a–c) Representative traces 
of HEK293T cells transiently transfected with wild type (WT) BEST1 plus either p.Ile38Ser (a), p.Ala195Val 
(b), or p.Trp93Cys (c). (d) Current-voltage relationship of mock, WT, and co-transfection of WT and mutant 
BEST1. (e) The mean outward chord conductance (Gchord) in transfected HEK293T cells, calculated over 0 mV 
to +100 mV. Co-expression of WT and p.Ile38Ser BEST1 results into approximately one-third of the currents 
of WT BEST1, while p.Trp93Cys generated very small currents. The p.Ala195Val mutant, an autosomal 
recessive type, elicited large currents when co-expressed with WT BEST1. Data are presented as mean ± SEM. 
(Conductance values are provided in Supplementary Table S2. WT vs. WT + p.Ile38Ser, p < 0.01; WT + p.
Ile38Ser vs. WT + p.Ala195Val, p < 0.001; WT + p.Ile38Ser vs. WT + p.Trp93Cys, p < 0.01 by ANOVA followed 
by Newman-Keuls multiple comparison test, details are provided in Supplementary Table S2).
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In this study, we conducted a comprehensive clinical, genetic, and molecular evaluation of AVMD associated 
with a heterozygous mutation in BEST1. BEST1 mutation, detected in AVMD, showed intermediate deteriora-
tion of protein function. In vitro functional experiments showed that p.Ile38Ser is one of the BEST1 autosomal 
dominant mutations associated with AVMD. This study establishes a connection between clinical phenotypes and 
AVMD pathogenesis at the molecular level. The hypothesis that AVMD is a mild form of BVMD and presents the 
same spectrum is verified by molecular and physiological experiments.
Methods
Clinical investigation. This study was approved by the Institutional Review Board of the Yonsei University 
College of Medicine (IRB No. 4-2017-0097) and followed the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from the participant. A patient with AVMD was investigated in this study. The 
patient underwent a detailed ophthalmological examination, including best-corrected visual acuity, intraocular 
pressure measurement, slit-lamp examination, indirect ophthalmoscopy, fundus photography, fundus autofluo-
rescence imaging, spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography, and full-
field electroretinography (ERG), and EOG. Full-field ERG and EOG were performed according to the guidelines 
of the International Society for Clinical Electrophysiology of Vision (www.iscev.org). The normal range of the 
Arden ratio of the EOG (ratio of the light peak to the dark trough) is more than 1.8 for our laboratory.
Genetic analysis. Genetic analysis was performed as reported previously22. Genomic DNA was isolated 
from the subject’s blood using QIAamp RNA Blood Mini Kit (Cat. No. 51106, QIAGEN, Hilden, Germany). 
Each exon of the BEST1 gene was amplified from genomic DNA by polymerase chain reaction (PCR) using the 
intronic oligonucleotide primers and PCR conditions described previously34. Each exon of the PRPH2, IMPG1, 
and IMPG2 genes was also amplified from genomic DNA by PCR using the intronic oligonucleotide primers 
(Supplementary Table S3). Each PCR was performed by using Maxime PCR PreMix (Cat. No. 25167, iNtRON 
Biotech., Seoul, Korea). PCR products were analyzed by direct sequencing using an Applied Biosystems (ABI) 
3730 DNA sequencer (ABI, Foster City, CA, USA).
We examined the most recent versions of dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), exome variant server 
(EVS; http://evs.gs.washington.edu/EVS/), and exome aggregation consortium (ExAC; http://exac.broadinstitute.
org/). We examined the NBK control database (397 healthy individuals) and our in-house whole exome sequenc-
ing data (59 subjects), which were described in our previous study21.
Plasmids and cell culture. Human embryonic kidney 293 T cells (HEK293T) and HeLa cells were cultured 
in Dulbecco’s modified Eagle medium (DMEM)-HG (Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
(v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin. The mammalian expression 
plasmids for hBEST1 WT, p.Ala195Val, and p.Trp93Cys were previously described22. The hBEST1 p.Ile38Ser 
mutant plasmids were generated by using PCR-based site-directed mutagenesis. Plasmids were transiently 
Figure 6. Predicted computational tertiary structure of wild-type (WT) and p.Ile38Ser hBEST1 proteins. 
4RDQ crystal structure was used as template. (a) Homopentameric structure of WT BEST1 full structure. Red 
dots represent outer membrane border and blue dots represent intracellular membrane border. Isoleucine 38 
position, which is located in the transmembrane (TM) domain 1, is highlighted in red. The yellow box region 
was magnified in (b) and (c). (b) The side chain of Ile38 in the TM1 domain was described, which consisted of 
a hydrophobic carbon chain (gray). The side chain protrudes toward the lipid membrane. (c) The side chain of 
Ser38 presents hydrophilic oxygen residue (red), which may generate a repulsive force with the hydrophobic 
lipid membrane.
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transfected into cells using Lipofectamine Plus (Invitrogen). For electrophysiological experiments, hBEST1 
plasmids without tags were transfected at a 9:1 ratio with a plasmid expressing the green fluorescence protein 
(pEGFP-N1). An average transfection rate over 90% was confirmed by transfection with a plasmid expressing 
green fluorescence protein (Supplementary Fig. S3). For surface biotinylation, immunocytochemistry, and immu-
noblotting, hBEST1 plasmids containing a Myc-tag were used.
Electrophysiology in cultured cells. Anion channel activities were measured in HEK293T cells using the 
whole-cell patch clamp techniques reported previously22, 35. Briefly, cells were transferred into a bath mounted 
on a stage with an inverted microscope (IX-70; Olympus, Tokyo, Japan). Conventional whole-cell clamp was 
achieved by rupturing the patch membrane after forming a gigaseal. The bath solution was perfused at 5 mL/min. 
The voltage and current recordings were performed at room temperature (22–25 °C). Patch pipettes with a free-tip 
resistance of approximately 2–5 MΩ were connected to the head stage of a patch-clamp amplifier (Axopatch-
700B; Molecular Devices, Sunnyvale, CA, USA). pCLAMP software v. 10.2 and Digidata-1440A (Molecular 
Devices) were used to acquire data and apply command pulses. AgCl reference electrodes were connected to the 
bath via a 1.5% agar bridge containing 3 M KCl solution. Voltage and current traces were stored and analyzed 
using Clampfit v. 10.2 and Origin v. 8.0 (OriginLab Corp., Northampton, MA, USA). Currents were sampled at 
5 kHz. All data were low pass-filtered at 1 kHz.
The bath solution for the whole-cell patch clamp contained 146 mM N-methyl-d-glucamine-Cl (NMDG-Cl), 
1 mM CaCl2, 1 mM MgCl2, 5 mM glucose, and 10 mM HEPES (pH 7.4). The pipette solution contained 148 mM 
NMDG-Cl, 1 mM MgCl2, 3 mM MgATP, 10 mM HEPES, and 5 mM ethylene glycol tetra-acetic acid (EGTA) (pH 
7.2).The free Ca2+ concentrations of the buffer solutions were fixed to 1 μM by adjusting the Ca2+ chelator EGTA 
(5 mM) and CaCl2 concentrations using WEBMAX-C software (http://www.stanford.edu/~cpatton/maxc.html). 
The osmolarity of the bath solution was set to be 10 mOsm higher than that of the pipette solution by adding 
sorbitol to suppress the volume-activated anion channels. To determine the current-voltage (I-V) relationship, 
the clamp mode was shifted to voltage clamp mode, and the I-V curve was obtained by applying step pulses from 
−100 to 100 mV (voltage interval: 20 mV; duration: 2 s; holding potential: 0 mV).
Surface biotinylation, immunoblotting, and detergent solubility assay. Surface biotinylation and 
immunoblotting were performed as described previously22. Transfected HEK293T cells were washed three times 
with ice-cold phosphate-buffered saline (PBS). The cells were then treated with sulfo-NHS-SS-biotin-containing 
buffer (Pierce, Rockford, IL, USA) for 30 min to biotinylate the plasma membrane proteins. After biotinylation, 
the cells were washed with quenching buffer to remove the excess biotin and washed twice again with PBS. The 
cells were harvested and incubated overnight with avidin solution (UltraLink Immobilized NeutrAvidin Beads 
10%, Pierce) at 4 °C. Avidin-bound complexes were washed three times and the biotinylated proteins were 
eluted in a 2X sample buffer. The protein samples were suspended in a sodium dodecyl sulfate (SDS) buffer 
and separated by SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred to a nitro-
cellulose membrane and blotted with the appropriate primary and secondary antibodies. The anti-Myc (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) antibody was used as the primary antibody, and an anti-mouse IgG 
(HRP) (Thermo Scientific, Rockford, IL, USA) antibody was used as the secondary antibody. Protein bands were 
detected by enhanced chemiluminescence (Amersham Biosciences, Buckinghamshire, UK).
Detergent solubility assay was performed as described previously36. Transfected HEK293T cells were washed 
twice with ice-cold PBS and lysed with 0.5% Triton X-100 (Tx) containing lysis buffer for 2 min on ice. After cen-
trifugation, the Tx-soluble fraction was collected and denatured in SDS buffer. The pellet containing Tx-insoluble 
proteins was sonicated and denatured in SDS buffer containing 9 M urea. The samples were analyzed by western 
blotting as described previously.
Immunocytochemistry. Immunocytochemistry was performed as described previously22. Cells grown on 
coverslips and tissue sections were fixed in 10% formalin for 10 min and permeabilized with 0.1% triton X-100 for 
10 min at room temperature. Nonspecific binding sites were blocked by incubation for 1 h at room temperature 
with 0.1 mL of phosphate buffered saline (PBS) containing 5% horse serum, 1% bovine serum albumin, and 0.1% 
gelatin (blocking medium). After blocking, cells were stained by incubation with appropriate primary antibod-
ies and then treated with fluorophore-tagged secondary antibodies. Fluorescent images were obtained with a 
Zeiss LSM 780 confocal microscope (Carl Zeiss, Berlin, Germany). Anti-myc (Santa Cruz Biotechnology), and 
anti-Na+-K+ ATPase (Abcam, Cambridge, MA, USA) were purchased from commercial sources.
Structure modeling. Structure modeling was performed as previously described37, 38. The template structure 
that was sequentially most similar to the hBEST1 was selected by using Blast sequence search against PDB. The 
calcium-activated chloride channel bestrophin-1 from chicken (pdb ID: 4RDQ) was selected. SWISS-MODEL 
was used to generate tertiary structure of the domain (SWISS-MODEL, http://swissmodel.expasy.org/). 
Molecular graphics and analyses were performed with the UCSF Chimera package (Chimera, http://www.cgl.
ucsf.edu/chimera).
Statistical analysis. The results are presented as the means ± SEM. Statistical analysis was performed with 
ANOVA followed by Newman-Keuls multiple comparison test as appropriate. P < 0.05 was considered statisti-
cally significant.
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